Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Rossi

Showing results (1-10 of 516) with videos related to

Pageof 52
Sort By:
Journal of Thoracic Disease|October 18, 2016
Relapsed small-cell lung cancer: platinum re-challenge or notAntonio Rossi
Cancers|September 9, 2020
Immunotherapy and NSCLC: The Long and Winding RoadAntonio Rossi
Expert Review of Clinical Pharmacology|May 28, 2016
Alectinib for ALK-positive non-small-cell lung cancerAntonio Rossi
The Lancet. Oncology|November 16, 2013
Cetuximab and non-small-cell lung cancer: end of the story?Antonio Rossi
Annals of Translational Medicine|November 22, 2016
Immunotherapy in small-cell lung cancer: at what point are we?Antonio Rossi
The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancerAntonio Rossi
Expert Review of Respiratory Medicine|September 13, 2019
New options for combination therapy for advanced non-squamous NSCLCAntonio Rossi
Expert Review of Vaccines|December 22, 2012
Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?Antonio Rossi
Journal of Thoracic Disease|July 20, 2018
Cetuximab in the treatment of advanced non-small cell lung cancer: FISHing for a miraculous catchLorenza Landi, Antonio Rossi
Expert Opinion on Emerging Drugs|May 17, 2019
Emerging angiogenesis inhibitors for non-small cell lung cancerUmberto Malapelle, Antonio Rossi
Pageof 52

Showing results (1-10 of 516) with videos related to

Sort By:
Pageof 52
Journal of Thoracic Disease|October 18, 2016
Relapsed small-cell lung cancer: platinum re-challenge or notAntonio Rossi
Cancers|September 9, 2020
Immunotherapy and NSCLC: The Long and Winding RoadAntonio Rossi
Expert Review of Clinical Pharmacology|May 28, 2016
Alectinib for ALK-positive non-small-cell lung cancerAntonio Rossi
The Lancet. Oncology|November 16, 2013
Cetuximab and non-small-cell lung cancer: end of the story?Antonio Rossi
Annals of Translational Medicine|November 22, 2016
Immunotherapy in small-cell lung cancer: at what point are we?Antonio Rossi
The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancerAntonio Rossi
Expert Review of Respiratory Medicine|September 13, 2019
New options for combination therapy for advanced non-squamous NSCLCAntonio Rossi
Expert Review of Vaccines|December 22, 2012
Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?Antonio Rossi
Journal of Thoracic Disease|July 20, 2018
Cetuximab in the treatment of advanced non-small cell lung cancer: FISHing for a miraculous catchLorenza Landi, Antonio Rossi
Expert Opinion on Emerging Drugs|May 17, 2019
Emerging angiogenesis inhibitors for non-small cell lung cancerUmberto Malapelle, Antonio Rossi
Pageof 52